logo-loader
viewOncimmune

Oncimmune reports successful large-scale lung cancer study

Oncimmune Holdings PLC (LON:ONC) chief executive Dr Adam Hill speaks to Proactive London as the firm announced the positive results of a large-scale lung cancer study.

The company’s EarlyCDT-Lung test was used alongside x-rays and CT scans to check for the disease.

A total of 12,210 people in Scotland were monitored for two years as part of the Early Cancer Detection Test in what is believed to be the largest randomised controlled assessment of its kind.

Quick facts: Oncimmune

Price: 36 GBX

AIM:ONC
Market: AIM
Market Cap: £22.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and...

on 1/11/19

2 min read